Aliases & Classifications for Bone Cancer

Aliases & Descriptions for Bone Cancer:

Name: Bone Cancer 12 41 14
Bone Carcinoma 12 14 69
Malignant Bone Neoplasm 12 69
Bone Neoplasms 42 69
Malignant Neoplasm of Bone 12
Malignant Osseous Tumor 12
Malignant Bone Tumour 12
Osteosarcoma of Bone 69
Osteogenic Neoplasm 69
Ca - Bone Cancer 12
Neoplasm of Bone 12
Bone Neoplasm 12
Osseous Tumor 12
Bone Tumour 12

Classifications:



External Ids:

Disease Ontology 12 DOID:184 DOID:2762
MeSH 42 D001859
NCIt 47 C9343 C36082

Summaries for Bone Cancer

MedlinePlus : 41 cancer that starts in a bone is uncommon. cancer that has spread to the bone from another part of the body is more common. there are three types of bone cancer: osteosarcoma - occurs most often between ages 10 and 19. it is more common in the knee and upper arm. chondrosarcoma - starts in cartilage, usually after age 40 ewing's sarcoma - occurs most often in children and teens under 19. it is more common in boys than girls. the most common symptom of bone cancer is pain. other symptoms vary, depending on the location and size of the cancer. surgery is often the main treatment for bone cancer. other treatments may include amputation, chemotherapy, and radiation therapy. because bone cancer can come back after treatment, regular follow-up visits are important. nih: national cancer institute

MalaCards based summary : Bone Cancer, also known as bone carcinoma, is related to chest wall bone cancer and primary bone cancer, and has symptoms including back pain, muscle cramp and sciatica. An important gene associated with Bone Cancer is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are ERK Signaling and Glioma. The drugs Quadramet and Xgeva have been mentioned in the context of this disorder. Affiliated tissues include bone, prostate and spinal cord, and related phenotypes are behavior/neurological and immune system

Disease Ontology : 12 A bone cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

Related Diseases for Bone Cancer

Diseases related to Bone Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 68)
id Related Disease Score Top Affiliating Genes
1 chest wall bone cancer 11.9
2 primary bone cancer 11.9
3 bone marrow cancer 11.0
4 ewing sarcoma 10.8
5 maxillary neoplasm 10.7
6 osteosarcoma, somatic 10.7
7 adamantinoma of long bones 10.7
8 bone squamous cell carcinoma 10.6
9 chondrosarcoma 10.5
10 jaw cancer 10.5
11 multiple enchondromatosis, maffucci type 10.5
12 orbital cancer 10.5
13 bone giant cell tumor 10.5
14 bone fracture 10.5
15 sternum cancer 10.5
16 femoral cancer 10.5
17 long bones of lower limb cancer 10.5
18 bone lymphoma 10.5
19 phka2-related phosphorylase kinase deficiency 10.3 TNFRSF11A TNFSF11
20 primary release disorder of platelets 10.2 BGLAP MRC2
21 epilepsy, idiopathic generalized 14 10.2 BGLAP TNFRSF11A TNFSF11
22 bulbomembranous urethral cancer 10.2 MMP9 TNFRSF11A TNFSF11
23 glossitis 10.2 P2RX7 RUNX2 TNFRSF11A TNFSF11
24 neovascular glaucoma 10.2 CCL2 IL6 TRPV1
25 acrorenal syndrome 10.1 BGLAP RUNX2 TNFSF11
26 pulmonary immaturity 10.1 EWSR1 MDM2 MTAP
27 bladder papillary transitional cell neoplasm 10.1 BGLAP IL6 TNFRSF11A TNFSF11
28 plague 10.1 CYCS MMP9 TNFSF11
29 infancy electroclinical syndrome 10.1 CCL2 IL6 MMP9
30 gestational choriocarcinoma 10.1 COL1A1 EWSR1 MDM2 TRPV1
31 histiocytosis 10.1 IL6 MMP9 TNFRSF11A TNFSF11
32 maroteaux stanescu cousin syndrome 10.1 BGLAP RUNX2 TNFRSF11A TNFSF11
33 chromosomal disease 10.1 BGLAP RUNX2 TNFRSF11A TNFSF11
34 ischemic bone disease 10.1 BGLAP RUNX2 TNFRSF11A TNFSF11
35 multifocal osteogenic sarcoma 10.1 CDKN2A MDM2 PDGFRB
36 intratubular embryonal carcinoma 10.1 CCL2 IL6 MMP9 TNFSF11
37 palmoplantar keratosis 10.1 CDKN2A EWSR1 MDM2
38 malignant adult ependymoma 10.1 BGLAP PDGFRB RUNX2
39 preretinal fibrosis 10.1 BGLAP MMP9 TNFRSF11A TNFSF11
40 familial mediterranean fever, ad 10.0 BGLAP TNFSF11
41 neonatal jaundice 10.0 CCL2 IL6 MMP9
42 grade iii astrocytoma 10.0 CDKN2A IL6 MDM2 PDGFRB
43 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 3 10.0 CDKN2A MDM2 MMP9 MTAP
44 autistic disorder 10.0 CCL2 IL6 MMP9 TNFRSF11A TNFSF11
45 hypogonadotropic hypogonadism 2 with or without anosmia 10.0 BGLAP COL1A1 RUNX2
46 optic nerve hypoplasia 10.0 CCL2 IL6 MMP9
47 adult astrocytic tumour 9.9 CDKN2A MDM2 MMP9 PDGFRB
48 dysbaric osteonecrosis 9.9 BGLAP COL1A1 IL6 RUNX2 TNFRSF11A TNFSF11
49 carnitine deficiency, systemic primary 9.9 BGLAP COL1A1 IL6 RUNX2 TNFRSF11A TNFSF11
50 neuronitis 9.7

Graphical network of the top 20 diseases related to Bone Cancer:



Diseases related to Bone Cancer

Symptoms & Phenotypes for Bone Cancer

UMLS symptoms related to Bone Cancer:


back pain, muscle cramp, sciatica

MGI Mouse Phenotypes related to Bone Cancer:

44 (show all 21)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.41 IL6 MDM2 MMP9 P2RX7 PDGFRB PDYN
2 immune system MP:0005387 10.41 ATF3 CCL2 CDKN2A COL1A1 CYCS IL6
3 growth/size/body region MP:0005378 10.39 ATF3 CDKN2A COL1A1 CYCS IL6 MDM2
4 cellular MP:0005384 10.36 CDKN2A COL1A1 CYCS IL6 MDM2 MMP9
5 hematopoietic system MP:0005397 10.35 CYCS IL6 ATF3 CDKN2A COL1A1 MDM2
6 homeostasis/metabolism MP:0005376 10.34 ATF3 CDKN2A COL1A1 IL6 MDM2 MMP9
7 cardiovascular system MP:0005385 10.33 CDKN2A COL1A1 CYCS IL6 MDM2 MMP9
8 integument MP:0010771 10.31 RUNX2 TNFRSF11A TNFSF11 TRPV1 ATF3 CDKN2A
9 endocrine/exocrine gland MP:0005379 10.26 COL1A1 CYCS IL6 MDM2 PDGFRB RUNX2
10 digestive/alimentary MP:0005381 10.22 MDM2 MMP9 PDGFRB PDYN RUNX2 TNFRSF11A
11 craniofacial MP:0005382 10.12 COL1A1 CYCS MDM2 PDGFRB RUNX2 TNFRSF11A
12 nervous system MP:0003631 10.11 ATF3 CDKN2A COL1A1 CYCS IL6 MDM2
13 limbs/digits/tail MP:0005371 10.08 COL1A1 MDM2 MMP9 P2RX7 PDGFRB RUNX2
14 liver/biliary system MP:0005370 10.06 CDKN2A COL1A1 IL6 MDM2 MTAP RUNX2
15 neoplasm MP:0002006 10.06 ATF3 CDKN2A COL1A1 IL6 MDM2 MMP9
16 muscle MP:0005369 10.03 CDKN2A COL1A1 IL6 MDM2 MMP9 PDGFRB
17 no phenotypic analysis MP:0003012 9.97 ATF3 CDKN2A COL1A1 MDM2 PDYN RUNX2
18 reproductive system MP:0005389 9.91 RUNX2 TNFRSF11A TNFSF11 CDKN2A COL1A1 IL6
19 respiratory system MP:0005388 9.81 ATF3 CDKN2A COL1A1 IL6 MMP9 MTAP
20 skeleton MP:0005390 9.77 ATF3 CDKN2A COL1A1 CYCS IL6 MDM2
21 vision/eye MP:0005391 9.23 ATF3 CDKN2A COL1A1 IL6 MMP9 PDGFRB

Drugs & Therapeutics for Bone Cancer

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Quadramet 17 SAMARIUM SM-153 LEXIDRONAM PENTASODIUM DuPont Merck Pharmaceutical Company Approved March 1997
2
Xgeva 17 46 DENOSUMAB Amgen Approved June 2013/ Approved November 2010
3
Xofigo 17 46 RADIUM RA-223 DICHLORIDE Bayer Healthcare Pharmaceuticals Approved May 2013
4
Zometa 17 46 ZOLEDRONIC ACID Novartis Approved August 2001/ Approved February 2002

Drugs for Bone Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1072)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
2
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 112809-51-5 3902
3
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754 657311
4
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
5
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
6
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 179324-69-7 387447 93860
7
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-02-2 5743
8
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
9
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 120511-73-1 2187
10
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-28-2 5757 53477783
11
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 2 71-58-9
12
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 57-83-0 5994
13
Cortisone acetate Approved Phase 4,Phase 3,Phase 2,Phase 1 1950-04-4, 50-04-4 5745
14
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 1 51-43-4 5816
15
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 107868-30-4 60198
16
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 10540-29-1 2733526
17
Toremifene Approved, Investigational Phase 4,Phase 3,Phase 2 89778-26-7 3005573
18
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
19
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
20
Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 52-24-4 5453
21
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1 58-18-4 6010
22
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-22-0 6013
23
Bleomycin Approved Phase 4,Phase 3,Phase 1,Phase 2 11056-06-7 5360373
24
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
25
Teriparatide Approved, Investigational Phase 4,Phase 3 52232-67-4 16133850
26
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
27
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
28
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
29
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58957-92-9 42890
30 sodium fluoride Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7681-49-4
31
Menthol Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 2216-51-5 16666
32
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
33
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
34
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
35
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
36
Fulvestrant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129453-61-8 104741 17756771
37
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
38
Dasatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 302962-49-8 3062316
39
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
40
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
41
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
42
Goserelin Approved Phase 4,Phase 3,Phase 2,Phase 1 65807-02-5 47725 5311128
43
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
44
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53714-56-0 3911 657181
45
Methamphetamine Approved, Illicit Phase 4 537-46-2 10836
46
Pamidronate Approved Phase 4,Phase 3,Phase 2,Phase 1 40391-99-9 4674
47
Etidronic acid Approved Phase 4,Phase 3,Phase 1 7414-83-7, 2809-21-4 3305
48
Adalimumab Approved Phase 4,Phase 3,Phase 2 331731-18-1 16219006
49
Methoxyflurane Approved, Vet_approved Phase 4 76-38-0 4116
50
Phentolamine Approved Phase 4 50-60-2 5775

Interventional clinical trials:

(show top 50) (show all 5156)
id Name Status NCT ID Phase
1 Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients Unknown status NCT00912938 Phase 4
2 Assessment of Quality of Life, Bone Density and Safety in Postmenopausal Breast Cancer Patients With Letrozole Therapy Unknown status NCT00913016 Phase 4
3 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4
4 Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer Unknown status NCT00030758 Phase 4
5 Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace) Unknown status NCT01908556 Phase 4
6 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4
7 Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors Unknown status NCT00111241 Phase 4
8 Vitamin D and Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4
9 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4
10 Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) Unknown status NCT02277587 Phase 4
11 Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer Unknown status NCT01612871 Phase 4
12 Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene Unknown status NCT01072318 Phase 4
13 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4
14 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4
15 Bioactive Glass Granules in Filling of Bone Defects Completed NCT01304121 Phase 4
16 A Study to Assess the Short Term Efficacy of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Pain Due to Breast Cancer Completed NCT02553707 Phase 4
17 A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Completed NCT02564107 Phase 4
18 HLA Sensitization Following Major Cortical Allograft Bone Procedures Completed NCT00160719 Phase 4
19 Physical Characteristics of Retrieved Massive Allografts Completed NCT00160758 Phase 4
20 FREE Study - Fracture Reduction Evaluation Completed NCT00211211 Phase 4
21 CAFE Study - Cancer Patient Fracture Evaluation Completed NCT00211237 Phase 4
22 Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients Completed NCT01129336 Phase 4
23 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4
24 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis Completed NCT00237159 Phase 4
25 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4
26 Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates Completed NCT00765687 Phase 4
27 Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer Completed NCT00334139 Phase 4
28 Pamidronate Administration in Breast Cancer Patients With Bone Metastases Completed NCT00128297 Phase 4
29 Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis Completed NCT00035997 Phase 4
30 Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid Completed NCT00172029 Phase 4
31 Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer Completed NCT00391690 Phase 4
32 Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Completed NCT00172003 Phase 4
33 Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases Completed NCT00219219 Phase 4
34 Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy Completed NCT00485953 Phase 4
35 Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer Completed NCT00219271 Phase 4
36 Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy Completed NCT00237146 Phase 4
37 Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases Completed NCT00434317 Phase 4
38 The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy Completed NCT00063609 Phase 4
39 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4
40 Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer Completed NCT00082277 Phase 4
41 Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer Completed NCT00859027 Phase 4
42 Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases Completed NCT00242554 Phase 4
43 Non-small Cell Lung Cancer Registry Completed NCT00099541 Phase 4
44 The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer Completed NCT01907880 Phase 4
45 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
46 Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions Completed NCT00171964 Phase 4
47 A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates Completed NCT00172016 Phase 4
48 A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation Completed NCT00067730 Phase 4
49 Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer Completed NCT00199485 Phase 4
50 Prevention of Osteoporosis in Breast Cancer Survivors Completed NCT00567606 Phase 4

Search NIH Clinical Center for Bone Cancer

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: bone neoplasms

Genetic Tests for Bone Cancer

Anatomical Context for Bone Cancer

MalaCards organs/tissues related to Bone Cancer:

39
Bone, Prostate, Spinal Cord, Dorsal Root Ganglion, Cortex, Cingulate Cortex, Myeloid

Publications for Bone Cancer

Articles related to Bone Cancer:

(show top 50) (show all 133)
id Title Authors Year
1
Normalizing GDNF expression in the spinal cord alleviates cutaneous hyperalgesia but not ongoing pain in a rat model of bone cancer pain. ( 27716965 )
2017
2
STAT1 as a downstream mediator of ERK signaling contributes to bone cancer pain by regulating MHC II expression in spinal microglia. ( 27742579 )
2017
3
Midazolam and ropivacaine act synergistically to inhibit bone cancer pain with different mechanisms in rats. ( 27841001 )
2017
4
WNT5A and Its Receptors in the Bone-Cancer Dialogue. ( 27355180 )
2016
5
Positive feedback regulation between microRNA-132 and CREB in spinal cord contributes to bone cancer pain in mice. ( 26919478 )
2016
6
The analgesic effect of rolipram is associated with the inhibition of the activation of the spinal astrocytic JNK/CCL2 pathway in bone cancer pain. ( 28025994 )
2016
7
Evaluation of Bone Cancer Pain Induced by Different Doses of Walker 256 Mammary Gland Carcinoma Cells. ( 27676678 )
2016
8
Negative regulation of REST on NR2B in spinal cord contributes to the development of bone cancer pain in mice. ( 27732941 )
2016
9
The perceptions of teenagers, young adults and professionals in the participation of bone cancer clinical trials. ( 26936110 )
2016
10
Suppression of the acute upregulation of phosphorylated-extracellular regulated kinase in ventral tegmental area by a I1-opioid receptor agonist is related to resistance to rewarding effects in a mouse model of bone cancer. ( 28034513 )
2016
11
MRI-guided focused ultrasound robotic system for the treatment of bone cancer. ( 27422861 )
2016
12
Dissociation between the relief of skeletal pain behaviors and skin hypersensitivity in a model of bone cancer pain. ( 27186713 )
2016
13
Analgesic effect and possible mechanism of SCH772984 intrathecal injection on rats with bone cancer pain. ( 27275127 )
2016
14
The Outcomes of Surgery and Chemoradiotherapy for Temporal Bone Cancer. ( 27466887 )
2016
15
MicroRNA-93-5p may participate in the formation of morphine tolerance in bone cancer pain mouse model by targeting Smad5. ( 27438143 )
2016
16
Effect of music therapy on pain behaviors in rats with bone cancer pain. ( 27273935 )
2016
17
Analgesic effects of adenylyl cyclase inhibitor NB001 on bone cancer pain in a mouse model. ( 27612915 )
2016
18
Targeted drug delivery of near IR fluorescent doxorubicin-conjugated poly(ethylene glycol) bisphosphonate nanoparticles for diagnosis and therapy of primary and metastatic bone cancer in a mouse model. ( 27919267 )
2016
19
Mechanisms of PDGF siRNA-mediated inhibition of bone cancer pain in the spinal cord. ( 27282805 )
2016
20
JNK in spinal cord facilitates bone cancer pain in rats through modulation of CXCL1. ( 26838746 )
2016
21
New Mechanism of Bone Cancer Pain: Tumor Tissue-Derived Endogenous Formaldehyde Induced Bone Cancer Pain via TRPV1 Activation. ( 26900062 )
2016
22
Mas-Related Gene (Mrg) C Activation Attenuates Bone Cancer Pain via Modulating Gi and NR2B. ( 27152740 )
2016
23
Activation of spinal MrgC-Gi-NR2B-nNOS signaling pathway by Mas oncogene-related gene C receptor agonist bovine adrenal medulla 8-22 attenuates bone cancer pain in mice. ( 27158400 )
2016
24
Modulation of Nav1.8 by Lysophosphatidic Acid in the Induction of Bone Cancer Pain. ( 27631681 )
2016
25
Effect of systemic injection of heterogenous and homogenous opioids on peripheral cellular immune response in rats with bone cancer pain: A comparative study. ( 27703511 )
2016
26
Systemic QX-314 Reduces Bone Cancer Pain through Selective Inhibition of Transient Receptor Potential Vanilloid Subfamily 1-expressing Primary Afferents in Mice. ( 27176211 )
2016
27
GPR30 disrupts the balance of GABAergic and glutamatergic transmission in the spinal cord driving to the development of bone cancer pain. ( 27608844 )
2016
28
Rho/ROCK acts downstream of lysophosphatidic acid receptor 1 in modulating P2X3 receptor-mediated bone cancer pain in rats. ( 27094551 )
2016
29
Dibenzoyl-methane Derivatives as a Potential and Exciting New Therapy for the Treatment of Childhood Bone Cancer. ( 27793931 )
2016
30
siRNA-mediated downregulation of GluN2B in the rostral anterior cingulate cortex attenuates mechanical allodynia and thermal hyperalgesia in a rat model of pain associated with bone cancer. ( 26889244 )
2016
31
Alleviating Bone Cancer-induced Mechanical Hypersensitivity by Inhibiting Neuronal Activity in the Anterior Cingulate Cortex. ( 27428822 )
2016
32
Development of imaging probes for bone cancer in animal models. A systematic review. ( 27565848 )
2016
33
Silencing Transient Receptor Potential Vanilloid Receptor Subtype I-Containing Sensory Neurons to Treat Bone Cancer Pain. ( 27176213 )
2016
34
Targeting glia for bone cancer pain. ( 27428617 )
2016
35
Minocycline attenuates bone cancer pain in rats by inhibiting NFI_B in spinal astrocytes. ( 27157092 )
2016
36
Effect of the ifenprodil administered into rostral anterior cingulate cortex on pain-related aversion in rats with bone cancer pain. ( 27871230 )
2016
37
Effects of Electroacupuncture Treatment on Bone Cancer Pain Model with Morphine Tolerance. ( 27672401 )
2016
38
Radiotherapy Suppresses Bone Cancer Pain through Inhibiting Activation of cAMP Signaling in Rat Dorsal Root Ganglion and Spinal Cord. ( 26989332 )
2016
39
A Single Intrathecal or Intraperitoneal Injection of CB2 Receptor Agonist Attenuates Bone Cancer Pain and Induces a Time-Dependent Modification of GRK2. ( 26935064 )
2016
40
Porous nano-hydroxyapatite/collagen scaffold containing drug-loaded ADM-PLGA microspheres for bone cancer treatment. ( 26975746 )
2016
41
Effect of estrogen on morphine- and oxycodone-induced antinociception in a female femur bone cancer pain model. ( 26802873 )
2016
42
Dual Therapeutic Action of a Neutralizing Anti-FGF2 Aptamer in Bone Disease and Bone Cancer Pain. ( 27506449 )
2016
43
CREB-regulated transcription coactivator 1 enhances CREB-dependent gene expression in spinal cord to maintain the bone cancer pain in mice. ( 27060162 )
2016
44
Fabrication and characterization of PVA/ODA-MMT-poly(MA-alt-1-octadecene)-g-graphene oxide e-spun nanofiber electrolytes and their response to bone cancer cells. ( 26838849 )
2016
45
Engagement of signaling pathways of protease-activated receptor 2 and I1-opioid receptor in bone cancer pain and morphine tolerance. ( 25708385 )
2015
46
Chemokines and Their Receptors: Potential Therapeutic Targets for Bone Cancer Pain. ( 26320755 )
2015
47
Nano-Hydroxyapatite Doped with Ho-166 as Drug Delivery System for Bone Cancer Therapy. ( 26552392 )
2015
48
Bone cancer incidence by morphological subtype: a global assessment. ( 26054913 )
2015
49
Delayed activation of spinal microglia contributes to the maintenance of bone cancer pain in female Wistar rats via P2X7 receptor and IL-18. ( 25995479 )
2015
50
Reducing bone cancer cell functions using selenium nanocomposites. ( 26454004 )
2015

Variations for Bone Cancer

Copy number variations for Bone Cancer from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 70082 12 58138784 58142025 Amplification SAS Bone cancer
2 70083 12 58141509 58146230 Amplification CDK4 Bone cancer
3 71134 12 67700000 68661632 Amplification MDM2 Bone cancer

Expression for Bone Cancer

Search GEO for disease gene expression data for Bone Cancer.

Pathways for Bone Cancer

Pathways related to Bone Cancer according to GeneCards Suite gene sharing:

(show all 21)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.76 ATF3 CCL2 CDKN2A COL1A1 CYCS IL6
2
Show member pathways
12.88 CDKN2A IL6 MDM2 MMP9 PDGFRB TNFSF11
3
Show member pathways
12.64 COL1A1 CYCS MMP9 TNFRSF11A TNFSF11 TRPV1
4 12.44 CDKN2A CYCS IL6 MDM2 MMP9 PDGFRB
5 12.31 ATF3 CDKN2A IL6 PDGFRB
6 11.97 EWSR1 IL6 MDM2 MMP9 RUNX2
7 11.93 CCL2 CDKN2A CYCS MDM2
8 11.84 CCL2 IL6 MMP9 PDYN
9 11.76 CDKN2A COL1A1 IL6 MDM2
10 11.7 CCL2 MMP9 PDGFRB
11 11.67 BGLAP IL6 MDM2
12 11.66 CCL2 IL6 TNFRSF11A TNFSF11
13 11.61 CDKN2A MDM2 MMP9
14 11.6 CDKN2A CYCS MDM2
15 11.51 CCL2 IL6 MMP9
16 11.45 BGLAP MDM2 RUNX2
17 11.36 BGLAP MMP9 RUNX2
18 11.15 BGLAP COL1A1 RUNX2 TNFSF11
19 10.99 BGLAP CCL2 IL6 MMP9
20 10.75 BGLAP COL1A1 IL6 RUNX2 TNFRSF11A TNFSF11
21 10.4 BGLAP COL1A1 PDGFRB TNFSF11

GO Terms for Bone Cancer

Cellular components related to Bone Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 IL6 P2RX7 TNFRSF11A TRPV1

Biological processes related to Bone Cancer according to GeneCards Suite gene sharing:

(show all 33)
id Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.99 CCL2 IL6 P2RX7 TNFRSF11A TRPV1
2 positive regulation of cell proliferation GO:0008284 9.97 ATF3 IL6 MDM2 PDGFRB RUNX2 TNFRSF11A
3 response to lipopolysaccharide GO:0032496 9.92 CCL2 IL6 P2RX7 TNFRSF11A
4 aging GO:0007568 9.91 BGLAP CCL2 IL6 PDGFRB
5 skeletal system development GO:0001501 9.87 BGLAP COL1A1 MMP9 RUNX2
6 positive regulation of gene expression GO:0010628 9.85 ATF3 IL6 MDM2 P2RX7 RLN2 RUNX2
7 response to organic cyclic compound GO:0014070 9.84 BGLAP IL6 P2RX7 PDGFRB
8 wound healing GO:0042060 9.83 COL1A1 IL6 PDGFRB
9 cellular response to organic cyclic compound GO:0071407 9.82 CCL2 MDM2 P2RX7
10 response to glucocorticoid GO:0051384 9.81 BGLAP CCL2 IL6
11 collagen catabolic process GO:0030574 9.8 COL1A1 MMP9 MRC2
12 positive regulation of apoptotic process GO:0043065 9.8 CDKN2A IL6 MMP9 P2RX7 PDGFRB TRPV1
13 response to nutrient levels GO:0031667 9.79 BGLAP COL1A1 IL6
14 cellular response to tumor necrosis factor GO:0071356 9.78 CCL2 COL1A1 IL6 TRPV1
15 cellular response to growth factor stimulus GO:0071363 9.77 BGLAP MDM2 TRPV1
16 response to heat GO:0009408 9.76 CCL2 IL6 TRPV1
17 osteoblast differentiation GO:0001649 9.76 BGLAP COL1A1 MRC2 RUNX2
18 skeletal system morphogenesis GO:0048705 9.73 COL1A1 P2RX7 RUNX2
19 response to drug GO:0042493 9.73 BGLAP CCL2 COL1A1 IL6 MDM2 P2RX7
20 response to bacterium GO:0009617 9.7 CCL2 IL6 P2RX7
21 response to antibiotic GO:0046677 9.69 CCL2 IL6 MDM2
22 cellular response to ATP GO:0071318 9.65 CCL2 TRPV1
23 negative regulation of bone resorption GO:0045779 9.65 IL6 P2RX7
24 PERK-mediated unfolded protein response GO:0036499 9.65 ATF3 CCL2
25 cellular response to alkaloid GO:0071312 9.64 MDM2 TRPV1
26 response to fluid shear stress GO:0034405 9.63 P2RX7 PDGFRB
27 regulation of vascular endothelial growth factor production GO:0010574 9.58 CCL2 IL6
28 TNFSF11-mediated signaling pathway GO:0071847 9.55 TNFRSF11A TNFSF11
29 monocyte chemotaxis GO:0002548 9.46 CCL2 IL6 TNFRSF11A TNFSF11
30 positive regulation of fever generation by positive regulation of prostaglandin secretion GO:0071812 9.43 TNFRSF11A TNFSF11
31 positive regulation of ERK1 and ERK2 cascade via TNFSF11-mediated signaling GO:0071848 9.4 TNFRSF11A TNFSF11
32 response to mechanical stimulus GO:0009612 9.35 BGLAP CCL2 COL1A1 IL6 P2RX7
33 ossification GO:0001503 9.1 BGLAP COL1A1 MMP9 RUNX2 TNFRSF11A TNFSF11

Molecular functions related to Bone Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.1 ATF3 COL1A1 EWSR1 MDM2 MMP9 TRPV1
2 platelet-derived growth factor binding GO:0048407 8.96 COL1A1 PDGFRB

Sources for Bone Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....